Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247304871> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2247304871 endingPage "19103" @default.
- W2247304871 startingPage "19103" @default.
- W2247304871 abstract "19103 Background: This study evaluated the effects of pemetrexed(P)single agent or combined with cisplatin(CI)or carboplatin(CA)in patients with malignant pleural mesothelioma.The results of Italian patients within the Expanded Access Program of P are presented. Methods: Chemotherapy-naive or previously-treated patients not eligible for curative surgery and with adequate organ function, received P 500 mg/m2combined with CI 75 mg/m2(P/CI,option 1),as single agent(P,option 2)or combined with CA at an AUC of 5 mg/mL-min(P/CA,option 3),all given i.v. every 21 days together with folic acid and vitamin B12. Results: A total of 1032 patients(275 P/CI,375 P and 382 P/CA)were treated(mean age 64.1years).886(253 P/CI, 292 P and 341 P/CA)were eenrolledvaluable for efficacy (48.6% with performance status ≥90). 26.8The following table shows the results of best response [n, (%)]. The one-year survival rate was 67.5%(95% C.I.46.2–88.9)with P/CI,75.0%(66.9–83.0)with P and 73.9%(59.3–88.4)with P/CA.The median number of cycles was 4.0 with P and 6.0 with other regimens.The relative dose intensity of P was greater than 96% with all options. Grade 3/4 neutropenia occurred in 20.2% of patients on P/CI,in 15.4% on PA and in 28.6% on P/CA,and was reported in 24.0% of naïve and 18.4% of previously-treated patients.Rates of grade 3/4 anemia were 10.6% with P/CI,11.6% with PA and 16.7 with P/CA. Conclusions: In this non-randomized study, the combination arms had a higher response rate compared to P alone, but no additional one-year survival benefit. Toxicity with P/CA was worse compared to P/CI or P alone. Table of Contents Chemo-naïve N(%) Previously treated N(%) P/CI N(%) P N(%) P/CA N(%) Resp. Rate 113 (20.9) 34 (10.0) 64 (25.3) 22 (7.5) 62 (18.2) 95%CI 17.5–24.6 7.0–13.7 20.1–31–1 4.8–11.2 14.2–22.7 Stable dis. 270 (49.9) 157 (46.0) 122 (48.2) 136 (46.6) 170 (49.9) Dis. Progr. 140 (25.9) 138 (40.5) 58 (22.9) 124 (42.5) 98 (28.7) No significant financial relationships to disclose." @default.
- W2247304871 created "2016-06-24" @default.
- W2247304871 creator A5021667109 @default.
- W2247304871 creator A5024854079 @default.
- W2247304871 creator A5053859150 @default.
- W2247304871 creator A5058647288 @default.
- W2247304871 creator A5087455044 @default.
- W2247304871 creator A5091060234 @default.
- W2247304871 date "2008-05-20" @default.
- W2247304871 modified "2023-09-26" @default.
- W2247304871 title "Use of pemetrexed with or without platin in malignant pleural mesothelioma in Italy" @default.
- W2247304871 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.19103" @default.
- W2247304871 hasPublicationYear "2008" @default.
- W2247304871 type Work @default.
- W2247304871 sameAs 2247304871 @default.
- W2247304871 citedByCount "0" @default.
- W2247304871 crossrefType "journal-article" @default.
- W2247304871 hasAuthorship W2247304871A5021667109 @default.
- W2247304871 hasAuthorship W2247304871A5024854079 @default.
- W2247304871 hasAuthorship W2247304871A5053859150 @default.
- W2247304871 hasAuthorship W2247304871A5058647288 @default.
- W2247304871 hasAuthorship W2247304871A5087455044 @default.
- W2247304871 hasAuthorship W2247304871A5091060234 @default.
- W2247304871 hasConcept C121332964 @default.
- W2247304871 hasConcept C126322002 @default.
- W2247304871 hasConcept C141071460 @default.
- W2247304871 hasConcept C142424586 @default.
- W2247304871 hasConcept C142724271 @default.
- W2247304871 hasConcept C2776694085 @default.
- W2247304871 hasConcept C2777063308 @default.
- W2247304871 hasConcept C2777240266 @default.
- W2247304871 hasConcept C2777407522 @default.
- W2247304871 hasConcept C2778239845 @default.
- W2247304871 hasConcept C2781451048 @default.
- W2247304871 hasConcept C71924100 @default.
- W2247304871 hasConcept C87355193 @default.
- W2247304871 hasConcept C90924648 @default.
- W2247304871 hasConceptScore W2247304871C121332964 @default.
- W2247304871 hasConceptScore W2247304871C126322002 @default.
- W2247304871 hasConceptScore W2247304871C141071460 @default.
- W2247304871 hasConceptScore W2247304871C142424586 @default.
- W2247304871 hasConceptScore W2247304871C142724271 @default.
- W2247304871 hasConceptScore W2247304871C2776694085 @default.
- W2247304871 hasConceptScore W2247304871C2777063308 @default.
- W2247304871 hasConceptScore W2247304871C2777240266 @default.
- W2247304871 hasConceptScore W2247304871C2777407522 @default.
- W2247304871 hasConceptScore W2247304871C2778239845 @default.
- W2247304871 hasConceptScore W2247304871C2781451048 @default.
- W2247304871 hasConceptScore W2247304871C71924100 @default.
- W2247304871 hasConceptScore W2247304871C87355193 @default.
- W2247304871 hasConceptScore W2247304871C90924648 @default.
- W2247304871 hasIssue "15_suppl" @default.
- W2247304871 hasLocation W22473048711 @default.
- W2247304871 hasOpenAccess W2247304871 @default.
- W2247304871 hasPrimaryLocation W22473048711 @default.
- W2247304871 hasRelatedWork W2006884367 @default.
- W2247304871 hasRelatedWork W2026218952 @default.
- W2247304871 hasRelatedWork W2165352664 @default.
- W2247304871 hasRelatedWork W2413537020 @default.
- W2247304871 hasRelatedWork W2473626106 @default.
- W2247304871 hasRelatedWork W2898388447 @default.
- W2247304871 hasRelatedWork W3029190832 @default.
- W2247304871 hasRelatedWork W3205509964 @default.
- W2247304871 hasRelatedWork W4206601548 @default.
- W2247304871 hasRelatedWork W4224212079 @default.
- W2247304871 hasVolume "26" @default.
- W2247304871 isParatext "false" @default.
- W2247304871 isRetracted "false" @default.
- W2247304871 magId "2247304871" @default.
- W2247304871 workType "article" @default.